Eurofins Scientific SE (0MV5.IL)
- Business Wire
Eurofins Achieves Organic Growth of 6.8% in Q1 2024, Ahead of Its Objectives
LUXEMBOURG, April 24, 2024--Regulatory News: The Eurofins (Paris:ERF) network of companies continues to deliver resilient growth:Reported revenues in Q1 2024 totalled €1,653m, an increase of 5.0% vs Q1 2023, driven by solid organic growth but slightly restrained by FX (-1.0%). The period also comprised nearly one less public working day, an effect that will mostly reverse in Q2 2024.Adjusted for public working days in Q1 2024, organic revenue growth7 in the Core Business (excluding COVID-19 rela
- Business Wire
Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 March 2024
LUXEMBOURG, April 05, 2024--Regulatory News: Eurofins Scientific SE (Paris:ERF):
- Business Wire
The Eurofins Network Expands Its Offering in Renal and Transplant Testing in the United States With the Acquisition of Ascend Clinical LLC
LUXEMBOURG, April 03, 2024--Regulatory News: Eurofins Scientific (EUFI.PA), a global leader in bioanalytical testing, announces the closing of its acquisition of Ascend Clinical, LLC ("Ascend"), the largest independent laboratory for kidney dialysis testing in the United States. Founded in 2000, Ascend operates a state-of-the-art laboratory in Sunnyvale, California and employs 170 staff. The company provides highly automated chemistry, hematology, microbiology and virology testing services to di
